EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Scientific deliverables Proposed document products

Eleven proposed technical documents would carry the evidence from each stage to the people who decide, and none of them is an FDA certificate

Each deliverable would be a EUTECNIQ technical document with defined contents, inputs and limits: what it would contain, which question it answers, who would do the work and what it is not.

Related: Quality and Six Sigma · Digital lab and traceability · CFR atlas

11proposed technical documents, one per decision
73content elements across the eleven documents
446of FDA's 1,938 Part 111 citations in fiscal 2025 named § 111.70, specifications
265named § 111.75, the tests that show specifications are met

Status. EUTECNIQ offers no services yet and has produced none of these documents. No prices or turnaround times are published. Partner work would go to qualified outside organizations under written agreements; none is signed.

Library

Each document answers one decision-level question at one stage of the pathway

Stages refer to the development pathway. Select a deliverable for its full entry.

Where each document sits on the pathway, and which documents feed othersProposed document set
Eleven proposed documents placed at the pathway stage each serves; the safety dossier builds on the identity passport and characterization package, and the NDIN package on all three1 Source2 Identity3 Characterize4 Safety5 Delivery6 Scale-up7 Regulatory8 Commercial08Supplierqualificationpackage01Ingredientidentitypassport02Analyticalcharacterizationpackage03Botanicalsafety dossier07Bioavailabilityand deliverytechnologydossier09Processdevelopmentand transferpackage05Regulatorymarket-accessassessment11IP and commer-cializationassessmentInputs to the safety dossier04NDIN development and notification support package · stages 2–7Identity passport, characterization packageand safety dossier06Ingredientcomparabilitypackage10Formulationapplicationspackage06IngredientcomparabilitypackageOne package, used at stage 3 or stage 6 (new supplier, site, process or scale)Builds on technicaldata from earlierstagesDocuments linked by stated inputsStated inputOther documents
Arrows show only the inputs each entry names: the safety dossier needs the identity passport and characterization package, because its conclusion applies to a specified material; the NDIN package needs all three.
Explanation, details and sources

Text version of the figure: each of the eleven documents, the pathway stage it serves and the question it answers.

DeliverablePathway stageThe question it answers
Ingredient identity passport2 · IdentityIs this the right species and plant part, free of plausible adulterants?
Analytical characterization package3 · CharacterizationWhat is in it, how much, and how variable is it?
Botanical safety dossier4 · SafetyIs the intended dose, population and duration supported?
NDIN development and notification support package2–7Is a notification needed, and is the evidence organized as FDA recommends?
Regulatory market-access assessment7 · RegulatoryWhere can it be sold, as what, with which claims?
Ingredient comparability package3 and 6Is the new source, site or scale equivalent for its intended use?
Bioavailability and delivery technology dossier5 · DeliveryWhat limits absorption, and does the delivery system address it?
Supplier qualification package1 · SourceCan this supplier's material and documents be relied on?
Process development and transfer package6 · Scale-upCan the process make on-specification material at the next scale?
Formulation applications package5 · DeliveryHow does the ingredient behave in the customer's format?
IP and commercialization assessment8 · CommercialIs there something protectable, who would own it, and how would it be sold?
Why these documents

Specifications and the tests that show they are met are the Part 111 requirements FDA cites most, every year since 2019

Form 483 citations of 21 CFR Part 111 by section, fiscal years 2019–2025: select a year to sortFDA data
FDA, Inspection Observations spreadsheets FY2019–FY2025, Foods tab, rows citing 21 CFR 111 summed by section (retrieved Oct 24, 2026). FDA notes the files cover system-generated Form 483s only, not every observation.
Data table: citations by section and fiscal year
FDA Form 483 citations of 21 CFR Part 111, top 12 sections
SectionFY2019FY2020FY2021FY2022FY2023FY2024FY2025
§ 111.70 Specifications236150145271247366446
§ 111.75 Tests to show specifications are met1589276129104173265
§ 111.205 Master manufacturing record established72433062618895
§ 111.260 Batch record contents467625373585103
§ 111.103 Quality-control written procedures74383664546767
§ 111.255 Batch record established70393363626860
§ 111.210 Master manufacturing record contents45481539316893
§ 111.105 Quality-control personnel duties45252837474438
§ 111.453 Holding and distribution procedures44242132414049
§ 111.553 Complaint procedures37222233303040
§ 111.503 Returned-product procedures3013928283356
§ 111.123 Quality control of records and operations26171728273027
All Part 111 citations1,4448717041,2181,1731,5831,938

The characterization package, identity passport and supplier qualification package would document specifications and their basis; a citation history says nothing about any one firm.

Explanation, details and sources

An FDA Form 483 lists an investigator's observations at the end of an inspection; it is not a final agency determination. FDA's yearly spreadsheets count how often each regulation was cited on system-generated 483s. Section 111.70 requires specifications for components, in-process points, finished batches, labels and packaging; section 111.75 requires tests or examinations to determine whether they are met, including an identity test for each dietary-ingredient lot. The FY2024 and FY2025 files record citations at a coarser paragraph level than earlier years, so the figure sums by section.

Deliverables

What each document would contain, what it needs and where its claims stop

73 content elements across eleven documents: select a stage or a document to see what it would containProposed contents
Built from the “Contains” line of each entry below, split at semicolons. Stage groups follow the library table.
The same identity, composition and safety evidence would recur across several documentsProposed contents
Evidence elements by document: identity and composition data recur across the identity passport, characterization package and comparability package; safety evidence across the safety dossier and NDIN package01Identity passport02Characterization03Safety dossier04NDIN support05Market access06Comparability07Delivery dossier08Supplierqualification09Process transfer10Formulation11IP assessmentIdentity and compositionBotanical name, plant part, source; voucher or referencematerialIngredient identity passport contains: Botanical name, plant part, source; voucher or reference materialMacroscopic and microscopic descriptionIngredient identity passport contains: Macroscopic and microscopic descriptionChromatographic fingerprint and marker profile or contentIngredient identity passport contains: Chromatographic fingerprint and marker profile or contentAnalytical characterization package contains: Chromatographic fingerprint and marker profile or contentIngredient comparability package contains: Chromatographic fingerprint and marker profile or contentTargeted adulterant resultsIngredient identity passport contains: Targeted adulterant resultsContaminants: elements, pesticides, solvents, mycotoxins,microbesAnalytical characterization package contains: Contaminants: elements, pesticides, solvents, mycotoxins, microbesIngredient comparability package contains: Contaminants: elements, pesticides, solvents, mycotoxins, microbesPhysical attributes: moisture, particle or droplet size, surfacechargeAnalytical characterization package contains: Physical attributes: moisture, particle or droplet size, surface chargeIngredient comparability package contains: Physical attributes: moisture, particle or droplet size, surface chargeBioavailability and delivery technology dossier contains: Physical attributes: moisture, particle or droplet size, surface chargeMethod validation or verification summariesAnalytical characterization package contains: Method validation or verification summariesLot-to-lot variability or a statistical comparisonAnalytical characterization package contains: Lot-to-lot variability or a statistical comparisonIngredient comparability package contains: Lot-to-lot variability or a statistical comparisonSpecification proposed or justifiedIngredient identity passport contains: Specification proposed or justifiedAnalytical characterization package contains: Specification proposed or justifiedFormulation applications package contains: Specification proposed or justifiedConfirmatory testing of supplier certificates across lotsSupplier qualification package contains: Confirmatory testing of supplier certificates across lotsSafety and regulatoryIntended conditions of use and an exposure estimateBotanical safety dossier contains: Intended conditions of use and an exposure estimateHistory of useBotanical safety dossier contains: History of useNDIN development and notification support package contains: History of useToxicology, human and adverse-event data reviewBotanical safety dossier contains: Toxicology, human and adverse-event data reviewInteraction assessmentBotanical safety dossier contains: Interaction assessmentSafety narrativeBotanical safety dossier contains: Safety narrativeNDIN development and notification support package contains: Safety narrativeGap analysis, testing plan or evidence gapsBotanical safety dossier contains: Gap analysis, testing plan or evidence gapsRegulatory market-access assessment contains: Gap analysis, testing plan or evidence gapsClassification, regulatory status and claims boundariesNDIN development and notification support package contains: Classification, regulatory status and claims boundariesRegulatory market-access assessment contains: Classification, regulatory status and claims boundariesFiling checklist (21 CFR 190.6(b)) or filings each marketrequiresNDIN development and notification support package contains: Filing checklist (21 CFR 190.6(b)) or filings each market requiresRegulatory market-access assessment contains: Filing checklist (21 CFR 190.6(b)) or filings each market requiresProcess and productProcessing history, manufacturing or process descriptionIngredient identity passport contains: Processing history, manufacturing or process descriptionNDIN development and notification support package contains: Processing history, manufacturing or process descriptionProcess development and transfer package contains: Processing history, manufacturing or process descriptionMass and energy balances; CPPs and CQAs with rangesProcess development and transfer package contains: Mass and energy balances; CPPs and CQAs with rangesStability attributes, data or protocolIngredient comparability package contains: Stability attributes, data or protocolBioavailability and delivery technology dossier contains: Stability attributes, data or protocolFormulation applications package contains: Stability attributes, data or protocolIn vitro dissolution and digestionBioavailability and delivery technology dossier contains: In vitro dissolution and digestionHuman pharmacokinetic study designBioavailability and delivery technology dossier contains: Human pharmacokinetic study designAcceptance criteria set before testing or transferIngredient comparability package contains: Acceptance criteria set before testing or transferProcess development and transfer package contains: Acceptance criteria set before testing or transferRisk assessment, ranking or residual risksIngredient comparability package contains: Risk assessment, ranking or residual risksSupplier qualification package contains: Risk assessment, ranking or residual risksProcess development and transfer package contains: Risk assessment, ranking or residual risksIP and commercialization assessment contains: Risk assessment, ranking or residual risksSupplier and IPSupplier questionnaire, audit report, approval andrequalificationSupplier qualification package contains: Supplier questionnaire, audit report, approval and requalificationPrior-art landscape, ownership mapping, protection optionsIP and commercialization assessment contains: Prior-art landscape, ownership mapping, protection options
A dot means the entry lists that element under "Contains". Column numbers follow the library table above.
Laboratory work would start in house; toxicology, human studies, counsel and commercial scale would go to partnersProposed division of work
Who would do the work for each of the eleven documents: planned in house, at pilot scale in Phase II, or with a type of qualified external partnerIn house, Phase IIn house, phase not statedIn house, Phase IIQualified partnerIn housePilot scale(Phase II)PartnerlaboratoriesCROs, clinical,bioanalysisIndependentexpertsCounsel andconsultantsIn-countryauditorsContractmanufacturersQualified external partners01Ingredient identity passportIngredient identity passport: In house, Microscopy, HPTLC, HPLC, LC-MSMicroscopy,HPTLC, HPLC,LC-MSIngredient identity passport: Partner laboratories, DNA barcoding, NMRDNAbarcoding,NMR02Analytical characterizationpackageAnalytical characterization package: In house, UHPLC, LC-MS/MS, GC-MS, ICP-MS, microbiologyUHPLC,LC-MS/MS,GC-MS,ICP-MS,microbiologyAnalytical characterization package: Partner laboratories, Accredited labs: out-of-scope testsAccreditedlabs:out-of-scopetests03Botanical safety dossierBotanical safety dossier: In house, Exposure, literature, writingExposure,literature,writingBotanical safety dossier: CROs, clinical, bioanalysis, Toxicology studiesToxicologystudiesBotanical safety dossier: Independent experts, Expert reviewExpert review04NDIN development andnotification support packageNDIN development and notification support package: In house, Technical assemblyTechnicalassemblyNDIN development and notification support package: Independent experts, Toxicology expertsToxicologyexpertsNDIN development and notification support package: Counsel and consultants, Regulatory counselRegulatorycounsel05Regulatory market-accessassessmentRegulatory market-access assessment: In house, Regulatory scienceRegulatoryscienceRegulatory market-access assessment: Counsel and consultants, Counsel, in-country consultantsCounsel,in-countryconsultants06Ingredient comparabilitypackageIngredient comparability package: In house, AnalyticsAnalyticsIngredient comparability package: Pilot scale (Phase II), Pilot-scale lotsPilot-scale lotsIngredient comparability package: Partner laboratories, Orthogonal testsOrthogonaltests07Bioavailability and deliverytechnology dossierBioavailability and delivery technology dossier: In house, Formulation, in vitro testsFormulation, invitro testsBioavailability and delivery technology dossier: CROs, clinical, bioanalysis, Human PK, plasma bioanalysisHuman PK,plasmabioanalysis08Supplier qualification packageSupplier qualification package: In house, Analytics and qualityAnalytics andqualitySupplier qualification package: In-country auditors, Foreign-site auditsForeign-siteaudits09Process development andtransfer packageProcess development and transfer package: In house, Laboratory scaleLaboratoryscaleProcess development and transfer package: Pilot scale (Phase II), Pilot plant, after its gatePilot plant,after its gateProcess development and transfer package: Contract manufacturers, Commercial scale until Phase IIICommercialscale untilPhase III10Formulation applicationspackageFormulation applications package: In house, Formulation laboratoryFormulationlaboratoryFormulation applications package: Contract manufacturers, Commercial production, or by the customerCommercialproduction, orby thecustomer11IP and commercializationassessmentIP and commercialization assessment: In house, Technical landscapingTechnicallandscapingIP and commercialization assessment: Counsel and consultants, Patent attorney or agentPatent attorneyor agent
Phase I is proposed for 2027; Phase II follows only after its gate (facilities roadmap). The NDIN notifier is the manufacturer or distributor of the ingredient or the supplement (21 CFR 190.6).
None of the eleven documents is a certificate, an approval or a legal opinionLimits set by rule and evidence
What each of the eleven proposed documents is not, with the reason or ruleDocumentIs not, and why01Ingredient identity passport≠A certificate of authenticity from any authorityDescribes the lots tested. Future lots still need the identity test the buyer's own rules require, 21 CFR111.75(a)(1)(i)02Analytical characterization package≠An accredited test reportEUTECNIQ holds no ISO/IEC 17025 accreditation, which would cover only listed tests. Results representa lot only if sampling was representative03Botanical safety dossier≠An FDA determination of safety, or a GRAS conclusion by itselfCovers the specified material only; a differently processed extract or a nanomaterial form needs its ownevaluation04NDIN development and notificationsupport package≠FDA approvalFDA does not approve NDI notifications; an acknowledgment without objection is not an FDA finding ofsafety. Not legal advice; no outcome promised05Regulatory market-accessassessment≠Legal advice or an authorizationClassification depends on intended use and claims, and rules change; every assessment is dated06Ingredient comparability package≠Proof of equivalent effect in peopleComparability is shown attribute by attribute; a change may still need regulatory assessment (FDA'sviews are in draft guidance)07Bioavailability and deliverytechnology dossier≠Evidence of bioavailability on its ownNanoemulsion stability is not bioavailability; in vitro bioaccessibility is not systemic exposure; higherexposure is not clinical benefit08Supplier qualification package≠A certification of the supplierA qualified certificate does not remove the identity test of each dietary-ingredient lot, 21 CFR111.75(a)(1); the buyer's duties remain09Process development and transferpackage≠A validated commercial processProcess validation at the receiving site is that site's responsibility; drug process validation is outside theplan10Formulation applications package≠A validated shelf lifeAccelerated data support a shelf life but do not establish one; prototypes are not commercial products11IP and commercializationassessment≠A legal, patentability or freedom-to-operate opinionEUTECNIQ owns no patents; the founder's patents are assigned to YazakiWhat each of the eleven proposed documents is not, with the reason or rule01 Ingredient identity passport≠A certificate of authenticity from any authorityDescribes the lots tested. Future lots still need theidentity test the buyer's own rules require, 21 CFR111.75(a)(1)(i)02 Analytical characterization package≠An accredited test reportEUTECNIQ holds no ISO/IEC 17025 accreditation,which would cover only listed tests. Resultsrepresent a lot only if sampling was representative03 Botanical safety dossier≠An FDA determination of safety, or a GRASconclusion by itselfCovers the specified material only; a differentlyprocessed extract or a nanomaterial form needs itsown evaluation04 NDIN development and notification supportpackage≠FDA approvalFDA does not approve NDI notifications; anacknowledgment without objection is not an FDAfinding of safety. Not legal advice; no outcomepromised05 Regulatory market-access assessment≠Legal advice or an authorizationClassification depends on intended use and claims,and rules change; every assessment is dated06 Ingredient comparability package≠Proof of equivalent effect in peopleComparability is shown attribute by attribute; achange may still need regulatory assessment (FDA'sviews are in draft guidance)07 Bioavailability and delivery technology dossier≠Evidence of bioavailability on its ownNanoemulsion stability is not bioavailability; in vitrobioaccessibility is not systemic exposure; higherexposure is not clinical benefit08 Supplier qualification package≠A certification of the supplierA qualified certificate does not remove the identitytest of each dietary-ingredient lot, 21 CFR111.75(a)(1); the buyer's duties remain09 Process development and transfer package≠A validated commercial processProcess validation at the receiving site is that site'sresponsibility; drug process validation is outside theplan10 Formulation applications package≠A validated shelf lifeAccelerated data support a shelf life but do notestablish one; prototypes are not commercialproducts11 IP and commercialization assessment≠A legal, patentability or freedom-to-operateopinionEUTECNIQ owns no patents; the founder's patentsare assigned to Yazaki
eCFR, 21 CFR 111.75 and 190.6, current to Oct 21, 2026; FDA, NDI identity and safety final guidance (Oct 2026); ILAC-P8:11/2023 on accreditation claims. Not legal advice.
Full entries for all eleven documents: contains, answers, typical inputs, who would do the work, what it is not
01

Ingredient identity passport

Phase IPartner · DNA, NMR
Contains
Accepted botanical name with author, plant part and source description; voucher or reference-material record; macroscopic and microscopic description; HPTLC fingerprint and HPLC or LC-MS marker profile against authenticated reference material; targeted adulterant results; processing history for extracts; the identity specification proposed for routine lots.
Answers
Is this the right species and plant part? Which adulterants are plausible, and were they excluded? How should identity be confirmed on every future lot?
Typical inputs
Samples from several lots; supplier documents; authenticated reference material or a voucher specimen.
Who would do the work
In house, Phase I: microscopy, HPTLC, HPLC and LC-MS. Partner: DNA barcoding of crude material and NMR.
What it is not
Not a certificate of authenticity from any authority. It describes the lots tested and does not certify future lots, which still need the identity test the buyer's own rules require (21 CFR 111.75(a)(1)(i)).
02

Analytical characterization package

Phase IPartner · out-of-scope tests
Contains
Quantitation of marker or active compounds with method summaries; chromatographic fingerprint and untargeted profile; elemental impurities, pesticide residues, residual solvents, mycotoxins and microbial counts; moisture and particle size; method validation or verification summaries; lot-to-lot variability; a draft specification with its justification.
Answers
What is in the material, and at what level? How variable is it between lots? Which specification can be justified and measured reliably?
Typical inputs
Representative samples from several lots; reference standards; the intended market and product category.
Who would do the work
In house, Phase I: UHPLC, LC-MS/MS, GC-MS, ICP-MS and microbiology. Partner: accredited laboratories for tests outside the planned scope.
What it is not
Not an accredited test report: EUTECNIQ holds no ISO/IEC 17025 accreditation, and an accreditation would cover only listed tests. Results describe the samples tested and represent a lot only if sampling was representative.
03

Botanical safety dossier

Assessment in housePartner · CROs, experts
Contains
Intended conditions of use and an exposure estimate; documented history of use; review of toxicology, human and adverse-event data; constituents of concern and how the specification controls them; an interaction assessment; gap analysis and a proposed testing plan; a safety narrative.
Answers
Is the intended dose, population and duration supported? What could go wrong, and for whom? Which studies would close the remaining gaps?
Typical inputs
The identity passport and characterization package, because the conclusion applies to a specified material; intended use and dose; published literature; any existing studies.
Who would do the work
In house: exposure assessment, literature review and writing. Partner: toxicology studies at contract research organizations; independent expert review.
What it is not
Not an FDA determination of safety, and not a GRAS conclusion by itself. It covers the specified material only: a differently processed extract or a nanomaterial form needs its own evaluation.
04

NDIN development and notification support package

Assembly in housePartner · counsel
Contains
Analysis of whether a notification appears to be required, noting that FDA's guidance on that question is still draft; identity information organized to FDA's October 2026 final guidance; manufacturing description and specifications; history of use or other evidence of safety; the safety narrative and safety calculations; a checklist against 21 CFR 190.6(b); master-file considerations under FDA's April 2024 draft guidance.
Answers
Does this ingredient appear to need a notification? Is the identity and safety evidence organized as FDA recommends? What is missing?
Typical inputs
Identity passport, characterization package and safety dossier; intended conditions of use; regulatory counsel's view.
Who would do the work
In house: technical assembly. Partner: regulatory counsel and toxicology experts. The notifier is the manufacturer or distributor of the ingredient or the supplement (21 CFR 190.6).
What it is not
Not FDA approval. FDA does not approve NDI notifications, and an acknowledgment without objection is not an independent FDA finding of safety. Not legal advice, and no outcome is promised.
05

Regulatory market-access assessment

In housePartner · in-country counsel
Contains
Classification of the intended product in each target market by intended use; the ingredient's status, including existing authorizations or novel status; claims boundaries; the filings each market requires and who must hold them; evidence gaps; a recommended order of work.
Answers
In which markets can this be sold, as what, and with which claims? Which filings or evidence come first?
Typical inputs
Product concept, composition and specifications; target markets; intended claims.
Who would do the work
In house: regulatory science. Partner: regulatory counsel and in-country consultants. See international market access.
What it is not
Not legal advice and not an authorization. Classification depends on intended use and claims, and rules change; every assessment is dated.
06

Ingredient comparability package

Phase IPilot lots · Phase II
Contains
A side-by-side comparison of a new supplier, site, process or scale against reference lots: identity, fingerprint similarity, marker content, impurity profile, physical attributes and stability-indicating attributes; acceptance criteria set before testing; a statistical comparison; the conclusion and residual risks.
Answers
Is material from the new source, process or scale equivalent for its intended use? Does the change raise new safety or regulatory questions?
Typical inputs
Reference lots and new lots; a description of the change; current specifications.
Who would do the work
In house: Phase I analytics, and pilot-scale lots from Phase II. Partner: orthogonal tests outside the planned scope.
What it is not
Not proof of equivalent effect in people: comparability is shown attribute by attribute. A manufacturing change may still need regulatory assessment, and FDA's views on manufacturing changes and NDI status are in draft guidance.
07

Bioavailability and delivery technology dossier

Phase IPartner · human PK
Contains
A physicochemical profile (solubility, partitioning, ionization, stability); the identified limit to absorption; the rationale for the chosen delivery system; formulation characterization (droplet or particle size distribution, surface charge, encapsulation efficiency, physical stability); in vitro dissolution and digestion results; a human pharmacokinetic study design if exposure claims are intended.
Answers
What limits absorption: solubility, dissolution, permeability or metabolism? Which delivery approach addresses that limit? What evidence would show higher exposure in people?
Typical inputs
A characterized active or extract; target dose and format; published pharmacokinetic data.
Who would do the work
In house, Phase I: formulation and in vitro testing. Partner: human pharmacokinetic studies and plasma bioanalysis. See advanced delivery.
What it is not
Not evidence of bioavailability on its own. Nanoemulsion stability is not demonstrated bioavailability, in vitro bioaccessibility is not systemic exposure, and higher exposure is not clinical benefit.
08

Supplier qualification package

Phase IPartner · in-country audits
Contains
Supplier questionnaire and document review; an audit report, onsite or remote and sized to risk; confirmatory testing of the supplier's certificate results across several lots; a risk ranking; the approval decision and requalification schedule; FSVP or supply-chain program notes for importers.
Answers
Can this supplier's material and documents be relied on? Which tests must the buyer still run? How often should the supplier be re-verified?
Typical inputs
Supplier documents; samples from several lots; site access for an audit.
Who would do the work
In house, Phase I: analytics and quality. Partner: in-country auditors for foreign sites. See global ingredients.
What it is not
Not a certification of the supplier by FDA or anyone else. A qualified certificate does not remove the identity test required for each dietary-ingredient lot (21 CFR 111.75(a)(1)), and the buyer's own obligations remain.
09

Process development and transfer package

Lab · Phase IPilot · Phase IIPartner · CMOs
Contains
Process description and flow diagram; mass and energy balances; critical process parameters and critical quality attributes with their ranges; scale-up rationale; equipment and utility needs; in-process controls; cleaning considerations; a draft master manufacturing record; pilot batch data; a risk assessment; a transfer protocol with acceptance criteria.
Answers
Can this process make on-specification material at the next scale? Which parameters matter, and in what ranges? What does the receiving site need?
Typical inputs
The laboratory process; specifications; target scale and the receiving site's equipment.
Who would do the work
In house: laboratory scale in Phase I and the pilot plant in Phase II, after its gate. Partner: commercial-scale runs at contract manufacturers until Phase III.
What it is not
Not a validated commercial process: process validation at the receiving site is that site's responsibility. Not drug process validation, which is outside the plan.
10

Formulation applications package

Phase I
Contains
Prototype formulations in target formats such as capsules, powders, beverages or topical emulsions; excipient compatibility; physical and chemical stability under defined storage, including accelerated conditions; manufacturability notes; a proposed finished-product specification and stability protocol.
Answers
How does the ingredient behave in this format? Which concentration, excipients and process steps work? Which stability risks remain?
Typical inputs
The ingredient and its specification; target format and market; the customer's base formula, if any.
Who would do the work
In house, Phase I formulation laboratory. Partner: commercial production by the customer or a contract manufacturer.
What it is not
Not a validated shelf life: accelerated data support a shelf life but do not establish one. Prototypes are not commercial products, and the regulatory category depends on intended use and claims.
11

IP and commercialization assessment

In housePartner · patent counsel
Contains
A prior-art landscape of patents and literature; observations on what may be new; questions for counsel on patentability and freedom to operate; ownership and inventorship mapping under the governing agreements; protection options (patent, trade secret, know-how license, master file); commercial routes and their risks; third-party market data, labeled as such.
Answers
Is there something protectable? Who would own it? What should counsel review? Which commercial route fits?
Typical inputs
Technical data from earlier stages; agreements; target markets.
Who would do the work
In house: technical landscaping. Partner: a registered patent attorney or agent. See commercialization and licensing.
What it is not
Not a legal, patentability or freedom-to-operate opinion. EUTECNIQ owns no patents; the founder's patents are assigned to Yazaki.
Explanation, details and sources

Four views of the same eleven entries: contents, who would do the work, and what each is not. "In house" means a capability planned for a proposed facility phase; "partner" means a qualified external organization.

Common standard

Every document would show where each statement comes from and where its claims stop

A proposed house standard, so a reader can audit a conclusion without calling the author.

Five elements would be built into every deliverableSchematic, not a real document
Schematic of a proposed EUTECNIQ deliverable showing the five elements of the house standard: confidentiality and data-ownership terms agreed before work starts, a scope and limitations section before the conclusions, an evidence label on each statement, the method and version behind each result with raw data retained, and quality review with signatures and version history5 Before work startsConfidentiality and data-ownership terms agreedEUTECNIQ technical documentVersion number · approval statusScope and limitationsResultsMeasured by EUTECNIQMeasured by a partnerPublished literatureModel outputProposalMethod and method version · raw data retainedConclusionsAuthorQuality reviewApproval1 Scope and limitations firstWritten before the conclusions2 An evidence label on each statementMeasured by EUTECNIQ, measured by a partner, published literature, modeloutput or proposal3 Method and method versionBehind each result, with raw data retained4 Quality review and approvalApproval signatures and a version history
Proposed document standard for every EUTECNIQ deliverable; none has been produced.
Text version: the house standard and what no deliverable would claim

Built into every deliverable

  • An evidence label on each statement: measured by EUTECNIQ, measured by a partner, published literature, model output or proposal.
  • The method and method version behind each result, with raw data retained.
  • A scope and limitations section, written before the conclusions.
  • Quality review, approval signatures and a version history.
  • Confidentiality and data-ownership terms agreed before work starts.
Proposal

What no deliverable would claim

  • Identity passport≠Certificate of authenticity
  • Characterization package≠Accredited test report
  • Safety dossier≠FDA safety finding
  • NDIN support package≠FDA approval
  • Delivery dossier≠Demonstrated bioavailability
  • Stability data≠Validated shelf life

Sources: eCFR, 21 CFR 111.75 and 190.6, current to Oct 21, 2026; FDA, NDI identity and safety final guidance (Oct 2026) and NDI notification master file draft guidance (Apr 2024); ILAC-P8:11/2023 on accreditation claims. Not legal advice.

Which document would answer your question?

Describe the ingredient, the market and the decision ahead. EUTECNIQ is in formation; early conversations help define scope.

Discuss a deliverableSee the pathway